The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for roflumilast topical foam 0.3% (Zoryve, Arcutis) for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. Jennifer Soung, MD, Director of Clinical Research at Southern California Dermatology in Santa Ana, CA, discusses what the approval means for psoriasis patients and their providers.
